Last reviewed · How we verify
RBP-6000
RBP-6000 is a subcutaneous depot formulation of buprenorphine that provides sustained opioid receptor partial agonism for extended periods.
RBP-6000 is a subcutaneous depot formulation of buprenorphine that provides sustained opioid receptor partial agonism for extended periods. Used for Opioid use disorder (maintenance treatment).
At a glance
| Generic name | RBP-6000 |
|---|---|
| Also known as | atrigel buprenorphine, extended-release buprenorphine, Sublocade, Atrigel buprenorphine, buprenorphine |
| Sponsor | Indivior Inc. |
| Drug class | Opioid receptor partial agonist (long-acting depot) |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Substance Use Disorder |
| Phase | Phase 3 |
Mechanism of action
RBP-6000 is a long-acting subcutaneous injection containing buprenorphine, a partial agonist at the mu-opioid receptor. The depot formulation releases buprenorphine gradually over several weeks, maintaining therapeutic levels and reducing withdrawal symptoms and cravings in opioid use disorder. This extended-release approach improves medication adherence compared to daily oral formulations.
Approved indications
- Opioid use disorder (maintenance treatment)
Common side effects
- Injection site reactions
- Headache
- Constipation
- Nausea
- Hyperhidrosis
Key clinical trials
- Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users (PHASE4)
- Community Studies of Long Acting Buprenorphine (CoLAB) (PHASE3)
- An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery
- Open-Label Treatment Extension Study (PHASE3)
- Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder (PHASE2)
- Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder (PHASE3)
- Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects (PHASE2)
- Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RBP-6000 CI brief — competitive landscape report
- RBP-6000 updates RSS · CI watch RSS
- Indivior Inc. portfolio CI